Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

New England Journal of Medicine(2024)10.1056/nejmoa2401361Source: DataRank Database

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy is a research paper published in New England Journal of Medicine (2024). On theSindex it has a DataRank of 0. It has been cited 190 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access190 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 34.57)OA: greenTopics (56)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Takeshi Sugio ORCID,Troy Noordenbos ORCID,Shuyu Shi,Philip L. Bulterys ORCID,Chih Long Liu ORCID

Live enrichment

PubMed:38865660 PMC:PMC11338600 OpenAlex:https://openalex.org/W4399558037

National Institutes of Health

Grant: CA233975

NCI NIH HHS

Grant: P01 CA049605

NCI NIH HHS

Grant: R01 CA229766

NCI NIH HHS

Grant: R01 CA257655

NCI NIH HHS

Grant: R01 CA233975

NCI NIH HHS

Grant: R35 CA283888

National Institutes of Health

Grant: 5R01CA233975-04

A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy

National Institutes of Health

Grant: 5P01CA049605-08

MARROW GRAFTING FOR THE LYMPHOMAS

Leukemia and Lymphoma Society

FWCI

34.57

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

greenLicense: cc-by-nc-nd

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11338600/pdf/nihms-1989954.pdf

publisherhttp://www.nejm.org/doi/pdf/10.1056/NEJMoa2401361

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11338600

journalhttps://doi.org/10.1056/nejmoa2401361

Fields of Study

CAR-T cell therapy researchLymphoma Diagnosis and TreatmentVirus-based gene therapy research03 medical and health sciences0302 clinical medicineFemaleHumansMiddle AgedBiological ProductsClonal HematopoiesisHerpesvirus 4, HumanImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseLymphoma, T-CellNeoplasms, Second PrimaryReceptors, Chimeric AntigenAntineoplastic Agents, ImmunologicalVirus Integration

MeSH Terms

Antineoplastic Agents, ImmunologicalReceptors, Chimeric AntigenClonal HematopoiesisAdultAgedBiological ProductsHerpesvirus 4, HumanFemaleHumansMaleMiddle AgedImmunotherapy, AdoptiveLymphoma, T-CellLymphoma, Large B-Cell, DiffuseNeoplasms, Second PrimaryVirus Integration

Keywords

LymphomaMedicineCAR T-cell therapyOncologyInternal medicineCancer researchCancerChimeric antigen receptorImmunotherapyBiological ProductsHerpesvirus 4, HumanReceptors, Chimeric AntigenVirus IntegrationNeoplasms, Second PrimaryMiddle AgedLymphoma, T-CellImmunotherapy, AdoptiveAntineoplastic Agents, ImmunologicalHumansFemaleLymphoma, Large B-Cell, DiffuseClonal Hematopoiesis

Sustainable Development Goals

SDG 0: Good health and well-being